Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Neurology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

  • Susan Friend1Email author,
  • Sandra Richman2,
  • Gary Bloomgren2,
  • Lynda M. Cristiano2 and
  • Madé Wenten2
BMC NeurologyBMC series – open, inclusive and trusted201616:150

https://doi.org/10.1186/s12883-016-0674-4

Received: 29 October 2015

Accepted: 12 August 2016

Published: 24 August 2016

Abstract

Background

Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are currently advised to balance the potential benefits and potential risks of exposure when considering treatment options. This study was undertaken to evaluate pregnancy outcomes of women with MS or CD who were exposed to natalizumab at any time within 3 months prior to conception or during pregnancy. A pregnancy registry was created to better understand the effect of natalizumab exposure on pregnancy outcomes.

Methods

The Tysabri Pregnancy Exposure Registry was a global, observational exposure registration and follow-up study. Evaluations included spontaneous abortions (<22 weeks gestational age), fetal losses (≥22 weeks gestational age), ectopic pregnancies, elective or therapeutic terminations, stillbirths, birth defects, and live births. Birth defects were reviewed and coded in accordance with the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of birth defects.

Results

A total of 369 patients with MS and 7 patients with CD were enrolled prospectively, of whom 355 patients (99.4 %; 349 MS and 6 CD) had known pregnancy outcomes (including 8 twin sets). The spontaneous abortion rate was 9.0 % (n = 32; 95 % confidence interval [C. I.], 6.3–12.5 %). An independent advisory committee review determined the major birth defect rate to be 5.05 % (16 of 316 live births + 1 elective abortion; 95 % C. I., 2.9–8.1 %). The mean gestational age of the live-born infants was 38.3 weeks, and the mean birth weight was 3158.3 g.

Conclusions

Although the overall rate of birth defects was higher than that observed by the MACDP, these registry outcomes showed no specific pattern of malformations that would suggest a drug effect, and the spontaneous abortion rate was consistent with that of the general population.

Trial registration

ClinicalTrials.gov NCT00472992 (11 May 2007).

Keywords

Pregnancy outcomeMultiple sclerosisFetal developmentSpontaneous abortionLive birthFollow-up studies

Background

Women of childbearing potential comprise a considerable segment of the patient population affected by multiple sclerosis (MS) and Crohn’s disease (CD) and may be exposed to therapies around conception and during pregnancy. Two-thirds of patients with MS are women, with a peak onset between 20 and 34 years of age, and approximately 10 % have disease onset during pregnancy [13]. CD peak onset is between 15 and 35 years of age, and in some regions there is a slight female predominance (20–30 % more frequently in women), particularly in high-incidence areas [4]. Women with MS or CD should be counseled to balance the benefits and risks of exposure when considering treatment options before or during pregnancy [5].

Natalizumab (Tysabri®; Biogen, Cambridge, MA, USA) is a humanized monoclonal antibody indicated for relapsing-remitting MS (RRMS) [6] that prevents leukocyte migration into the brain and reduces inflammation in MS patients [7, 8]. Within the United States, natalizumab is also approved for treatment of patients with CD [6]; in CD, natalizumab inhibits leukocyte adhesion and migration into gut tissue [9]. Studies of natalizumab in MS have shown reduced relapse rates and disability progression, but less is known about its effects on pregnancy outcomes [10, 11]. Natalizumab is classified as a pregnancy category C drug, as potential fetal effects have been reported in animal studies [1214] and there is a paucity of well-controlled human studies [6]. Although some animal studies have shown that natalizumab can cross the placental barrier and produce hematologic effects on fetal guinea pigs and primates [6, 12, 14, 15], others have not shown fetal interaction [16]. Human studies and case reports have not shown increases in spontaneous abortions or birth defects; however, results are limited by small sample sizes [1720].

This study prospectively evaluated pregnancy outcomes of women with MS or CD who were exposed to natalizumab within the 3 months before conception or during pregnancy.

Methods

Study design

The Tysbari Pregnancy Exposure Registry (TPER; referred to as the Registry) was a global, observational, exposure registration and follow-up study of pregnant women with MS or CD. The Registry collected information routinely documented in the patient and infant medical record with no Registry-required interventions or procedures conducted.

Ethics, consent, and permissions

The Registry (ClinicalTrials.gov NCT00472992) was established in accordance with regulatory guidance for pregnancy registries [2123]. Independent ethics committees (Aspire Institutional Review Board, Santee, CA, USA, and Institutional Review Board Services, Auroria, ON, Canada) reviewed and approved this Registry protocol. This study was conducted in accordance with the ethical principles of Good Clinical Practice based on the International Conference on Harmonisation Harmonised Tripartite Guideline. All patients provided written informed consent and were free to withdraw participation in the Registry at any time.

Patients

Between February 14, 2007, and April 24, 2011, women with MS or CD who were exposed to natalizumab at any time within the 3 months prior to conception or during pregnancy and for whom the outcome of the pregnancy was unknown at the time of enrollment were eligible to be registered prospectively in the study. Patients included women enrolled from observational studies (TYGRIS [Tysabri Global Observational Program in Safety; NCT00477113 and NCT00483847] or CD INFORM [Crohn’s Disease Investigating Natalizumab through Further Observational Research and Monitoring; NCT00707512]) or who received natalizumab as a marketed product in the United States and the rest of the world (ROW). The Coordinating Center (CC) of the Registry monitored patients throughout pregnancy and monitored outcomes within 4 weeks after the estimated date of delivery (United States and ROW) and within 8–12 weeks post delivery (United States). The CC point-of-contact and schedule varied slightly based on the study setting.

Registry data collection

Information was collected about natalizumab exposure, potential confounding factors (e.g., medical history, concomitant medications, or smoking), pregnancy outcomes, spontaneous abortions, fetal losses including stillbirths, and ectopic pregnancies. In addition, data were collected for elective or therapeutic pregnancy terminations, live-born infants, and birth defects.

Birth defects were reviewed and coded by an independent birth defect evaluator (a specialist in pediatrics and genetics) in accordance with the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of birth defects [24]. A major birth defect was defined as one characterized by a major structural or chromosomal abnormality in any live or stillborn infant or electively terminated fetus; any other birth defect was classified as minor. The MACDP excludes birth defects that are attributable to prematurity alone or identified prior to 20 weeks’ gestation. At the end of the study, an independent scientific advisory committee, consisting of 3 experts in relevant specialties of teratology, epidemiology, and maternal and fetal medicine, evaluated all Registry outcomes.

Statistical analysis

A target sample size of 300 pregnancy outcomes was determined based on the ability to detect a 2-fold increase in spontaneous abortion and a 3-fold increase in fetal loss and any major birth defects over general population background rates with 80 % power at the 0.05 level of significance.

For the primary analysis, the major birth defect rate was calculated by dividing the number of infants with major birth defects by the total number of live births. Birth defect rates from the Registry were compared with available background rates from the MACDP in the US general population [25]. A further calculation of the birth defect rate was performed excluding those birth defects that were considered to be non-major defects by the MACDP [25]. The rate of spontaneous abortions was calculated by dividing the number of fetal losses at <22 weeks gestational age by the total number of pregnancies. Corresponding 95 % confidence intervals (C. I.s) were calculated for major birth defect and spontaneous abortion rates. Spontaneous abortion rates in the Registry were compared with general population rates reported in published literature [2628].

Results

Patients

The first patient was enrolled on February 14, 2007, and the last pregnancy outcome was obtained on April 24, 2012. A total of 376 patients were prospectively enrolled in the Registry, with 318 patients enrolled in the United States (TYGRIS, n = 19; CD INFORM, n = 2; non-study, n = 297) and 58 enrolled in the ROW (TYGRIS, n = 58). The majority of patients had MS; only 7 of 376 patients had CD. Of the 376 patients, 6 (1.6 %) withdrew consent and 15 (4.0 %) were lost to follow-up; 355 (94.4 %) patients (including 8 sets of twins) had known pregnancy outcomes, resulting in a total of 363 known outcomes (Fig. 1).
Fig. 1

Patients enrolled and outcome of pregnancy. aEight completed pregnancies resulted in twin births

The mean age of the study population was 30.4 years (standard deviation [SD], 5.15 years; range 16–45 years). Race was only collected in patients enrolled in the United States (N = 318). Of US patients enrolled, 73.3 % were White, 16.4 % were Black, 6.6 % were Hispanic, and 0.9 % were Asian. Of the 9 patients (2.8 %) listed as “other”, 3 identified as biracial and 1 patient each as European, Multi, Filipino, Persian, Middle Eastern, and unknown.

Maternal obstetric history and prenatal natalizumab use

The maternal characteristics of patients at enrollment are detailed in Table 1. More than half of the patients (58.8 %) had experienced ≥1 prior pregnancy. Reports of prior birth defects were rare; 2 patients reported prior offspring with birth defects/mental handicap. The mean gestational age at the time of enrollment was 11.8 weeks (range 3–39 weeks).
Table 1

Baseline characteristics of study population (N = 376)

Maternal characteristic

n (%)

Age

  ≤ 20 years

10 (2.7)

  > 20 to 30 years

181 (48.1)

  > 30 to 40 years

178 (47.3)

  > 40 to 50 years

7 (1.9)

Obstetric history

  ≥ 1 prior pregnancy

221 (58.8)

 1 prior pregnancy resulting in fetal stillbirth (≥ 22 weeks)

2 (0.5)

 1 prior miscarriage

53 (14.1)

 2 prior miscarriages

11 (2.9)

 3 prior miscarriages

4 (1.1)

 4 prior miscarriages

1 (0.3)

  > 4 prior miscarriages

2 (0.5)

  > 4 prior pregnancies resulting in fetal stillbirth (≥ 22 weeks)

1 (0.3)

 1 prior elective/therapeutic abortion

28 (7.4)

 2 prior elective/therapeutic abortions

4 (1.1)

 1 prior ectopic pregnancy

3 (0.8)

Concomitant medications

 Prenatal vitamins

168 (44.7)

 Baclofen

29 (7.7)

 Folic acid

22 (5.9)

 Modafinil

21 (5.6)

 Multivitamins

19 (5.1)

Prior medical history

 Chicken pox

294 (78.2)

 Urinary tract infection

135 (35.9)

 Abnormal Pap test

109 (29.0)

 Gynecological surgery

55 (14.6)

 Breathing disorder

46 (12.2)

 Sexually transmitted disease

39 (10.4)

 Breast cancer

1 (0.3)

 Cervical cancer

1 (0.3)

 Lymphoma

1 (0.3)

 Melanoma

1 (0.3)

Social risk factorsa

 Caffeine use

235 (62.5)

 Alcohol consumption

70 (18.6)

 Tobacco use

59 (15.7)

 Illicit drug use

7 (1.2)

aOf patients who reported caffeine, alcohol, tobacco, or illicit drug use at enrollment, 168 of 235 (71.5 %), 7 of 70 (10.0 %), 25 of 59 (42.4 %), and 1 of 7 (14.3 %), respectively, continued use during pregnancy

Most enrolled patients (n = 366; 97.3 %) had discontinued natalizumab use at the time of enrollment. Of the 376 patients enrolled, 71 (18.9 %) discontinued natalizumab during the 3-month period prior to conception, 288 (76.6 %) discontinued during the first trimester, and 7 (1.9 %) discontinued during the second trimester. Six patients discontinued natalizumab after enrollment: 2, 3, and 1 patients during the first, second, and third trimesters, respectively.

Pregnancy outcomes

Birth defects

Of the 363 pregnancy outcomes in 355 patients, 57 birth defects (minor or major) were confirmed in 30 infants (including 3 sets of twins) (Tables 2 and 3); of these, 29 were live births and 1 was an elective termination resulting from a birth defect. In the case of the elective termination, natalizumab exposure was during the 3 months prior to conception. Of the 29 live births with birth defects, all were born to mothers who were last exposed to natalizumab during preconception or in the first trimester. More than half of these infants (n = 17, 58.6 %) were last exposed between gestational weeks 1 and 4, while the remainder were last exposed within 90 days prior to the last menstrual period (n = 6, 20.7 %), between 5 and 8 weeks’ gestation (n = 5, 17.2 %), or between 9 and 13 weeks’ gestation (n = 1, 3.4 %). The mean age of mothers who had infants with birth defects was 31.8 years (range 24–45 years).
Table 2

Pregnancy outcome categorized by time of discontinuation of natalizumab

Outcome of pregnancy, n (%)

Before conception (n = 73)

First trimester (n = 275)

Second trimester (n = 10)

Third trimester (n = 1)

Continued during pregnancy (n = 4)

Total (N = 363)

Spontaneous abortions

0

32 (11.6)

0

0

0

32 (8.8)

Elective termination (fetal defects)

1 (1.4)

0

0

0

0

1 (0.3)

Elective termination (no fetal defects or unknown)

2 (2.7)

11 (4.0)

0

0

0

13 (3.6)

Stillbirths without fetal defects

1 (1.4)

0

0

0

0

1 (0.3)

Live birth with congenital anomaly

7 (9.6)a

22 (8.0)b

0

0

0

29 (8.0)

Live birth without congenital anomaly

62 (84.9)c

210 (76.4)a

10 (100)

1 (100)

4 (100)

287 (79.1)

aIncludes 2 sets of twins

bIncludes 1 set of twins

cIncludes 3 sets of twins

Table 3

All observed major and minor birth defects (per MACDP criteria [25]) by organ system

Organ system, birth defect

Major or minor birth defect

Number of events (n = 57)

Musculoskeletal (n = 11)

 Plagiocephalya

Minor

4

 Torticollisa

Major

4

 Hip dysplasia

Major

1

 Polydactyly

Major

1

 Absent right femur

Major

1

Cardiovascular (n = 10)

 Ventricular septal defectb

Major

3

 Patent foramen ovalec

Minor

2

 Atrial shunt

Major

1

 Patent ductus arteriosusc

Minor

1

 Supraventricular tachycardia

Minor

1

 Tetralogy of Fallot

Major

1

 Tricuspid valve atresia

Major

1

Skin (n = 9)

 Hemangioma

Minor

2

 Café-au-lait spot

Minor

1

 Irregular tragus

Minor

1

 Mongolian spot

Minor

1

 Small anterior fontanelle

Minor

1

 Subcutaneous cyst

Minor

1

 Unspecified anomaly of nose

Major

1

 Unspecified anomaly of toes

Minor

1

Genital disorders (n = 8)

 Chordee

Minor

2

 Hydrocele

Minor

2

 Undescended testicle

Minor

2

 Chordee with hypospadias

Major

1

 Penile concealment

Major

1

Neurologic (n = 6)

 Colpocephaly

Major

1

 Holoprosencephaly

Major

1

 Hydrocephalus

Major

1

 Myelomeningocele

Major

1

 Sacral dimple

Minor

1

 Unspecified agenesis of corpus callosum

Major

1

Renal (n = 5)

 Hydronephrosis

Major

2

 Cystic dysplasia

Major

1

 Renal dilation

Minor

1

 Vesicoureteral reflux

Major

1

Gastrointestinal (n = 4)

 Umbilical hernia

Minor

2

 Inguinal hernia

Minor

1

 Tight frenulum

Minor

1

Chromosome (n = 1)

 Partial trisomy 9d

Major

1

Endocrine (n = 1)

 Congenital hypothyroidism

Minor

1

Metabolic (n = 1)

 Phenylketonuria

Major

1

Ocular (n = 1)

 Disconjugate gaze

Major

1

aThree cases of plagiocephaly and 2 cases of torticollis occurred in 2 sets of twins

bNo cases occurred in a premature birth (i.e., <37 weeks)

cOne case occurred in a premature birth (35 weeks 4 days’ gestation)

dMaternal age was 46 years at enrollment

Of the 57 observed birth defects (Table 3), those characterized as a major structural or chromosomal abnormality in a live or stillborn infant or electively terminated fetus were identified in 25 infants/fetuses out of 317 cases (316 live births plus 1 elective termination), leading to an overall rate of major structural or chromosomal abnormality of 7.9 % (95 % C. I. 5.2–11.4 %). To facilitate comparison of Registry data with the birth defect rate calculated by MACDP, a further calculation of the major birth defect rate was performed to exclude those birth defects not considered to be major by the MACDP [25]. This resulted in 18 of 317 infants with major birth defects, representing a rate of 5.7 % (95 % C. I. 3.4–8.8 %). Finally, the Advisory Committee reviewed all available Registry data; of the 18 cases identified as major birth defects using MACDP criteria, 3 cases of torticollis were considered medically minor and were excluded. However, 1 case of congenital hypothyroidism, which had been excluded by MACDP criteria, was considered by the Committee to be a major defect and was included. Therefore, the final adjusted rate of major birth defects, as adjudicated by the Advisory Committee, was determined in 16 of 317 cases, or 5.05 % (95 % C. I. 2.90–8.11 %).

Birth defects with possible temporal relationship

A birth defect evaluator also assessed confirmed defects (minor and major) for a possible temporal relationship to natalizumab exposure. A total of 26 major and minor defects were judged to have a possible temporal relationship (i.e., the development of the defect and the timing of natalizumab exposure could not rule out a possible association), with 16 major defects in 12 infants and 10 minor defects in 7 infants (Table 4).
Table 4

Major and minor birth defects with possible temporal relationshipa to exposure

Major birth defects

Minor birth defects

Gestational age at last natalizumab dose

Maternal concomitant medications

Absent right femur

NA

4 weeks

Azelastine nasal, prenatal vitamins, zolpidem

Anomaly of nose, cystic dysplasia of kidney, holoprosencephaly

Sandal toe gap, small anterior fontanelle

3 weeks

Methylphenidate, prenatal vitamins

Atrial shunt

NA

1 week

Heparin sodium, prenatal vitamins

Chordee with hypospadias

NA

26 days

Fluvoxamine, hydrocodone/acetaminophen, lamotrigine, meperidine/promethazine, ondansetron hydrochloride, prenatal vitamins

Colpocephaly, hydrocephalus, partial agenesis of corpus callosum

NA

4 days

Methylprednisolone sodium succinate, sertraline hydrochloride

Hydronephrosis

NA

5 weeks

Levothyroxine, metformin, sertraline hydrochloride

Penile concealment

NA

3 weeks

Prenatal vitamins

Polydactyly

NA

5 days

Folic acid, insulin

Tetralogy of Fallot

NA

0 (29 days prior to LMP)

Duloxetine, prenatal vitamins, topiramate, trazodone

Torticollis

NA

8 weeks

Bupropion, methylprednisolone, pantoprazole, propoxyphene/ acetaminophen, topiramate

Tricuspid valve atresia

NA

3 weeks

NR

Ventricular septal defect

NA

1 day

NR

NA

Congenital hypothyroidism

4.5 weeks

Nitrofurantoin, prenatal vitamins, Rh0(D) immune globulin, venlafaxine hydrochloride

NA

Irregular tragus, umbilical hernia

11 weeks

Prenatal vitamins

NA

Mongolian spot

3 weeks

Escitalopram, hydrocodone, levothyroxine, modafinil, prenatal vitamins

NA

Sacral dimple, umbilical hernia

5 weeks

Prenatal vitamins, valacyclovir

NA

Subcutaneous cyst

3 weeks

Prenatal vitamins

NA

Tight frenulum

3 days

Prenatal vitamins, tizanidine

Abbreviations: LMP last menstrual period, NA not applicable, NR not reported

a Potential relevance of the timing of natalizumab exposure to the birth defect(s) was evaluated and coded by the geneticist as “known cause”, “unknown cause”, “no association”, or “possible association”

Spontaneous abortions and fetal demise

Among the 355 pregnancies resulting in 363 known pregnancy outcomes, mean gestational age at enrollment was 11.8 weeks (SD, 6.8 weeks; range 3–39 weeks). In the 32 spontaneous abortions observed, the mean gestational age at enrollment was 5.5 weeks (SD, 2.0 weeks; range 4–13 weeks). Thus, the rate of spontaneous abortion (defined as fetal loss prior to 22 weeks’ gestation) among pregnancies with known outcomes was 9.0 % (95 % C. I. 6.3–12.5 %). Of the 355 pregnancies with known outcomes, 339 were enrolled prior to 22 weeks’ gestation; the rate of spontaneous abortion among these 339 pregnancies was 9.4 % (95 % C. I. 6.6–13.1 %). One stillbirth (0.3 %) was reported, and 14 patients (3.9 %) had elective terminations, 1 with a birth defect. No ectopic pregnancies were reported.

Physical attributes of live born infants

Of the 316 live born infants, 287 (90.8 %) were born without congenital anomaly. There were 148 males (46.8 %) and 163 females (51.6 %); gender was not recorded for 5 infants (1.6 %). The mean gestational age at birth was 38.3 weeks (range 26–43 weeks). The majority of infants (267 of 316, 84.5 %) were born at term (≥37 weeks); 48 (15.2 %) were born prematurely, and gestational age at birth was not recorded for 1 infant (0.3 %). At birth, mean APGAR (appearance, pulse, grimace, activity, and respiration) scores were 8.0 (range 1–10) at 1 min, 8.9 (range 2–10) at 5 min, and 9.6 (range 6–10) at 10 min; mean birth weight was 3161.7 g (95 % C. I. 3099.5–3223.9 g), mean infant length was 49.7 cm (range 34–56 cm), and mean head circumference was 35.2 cm (range 30–89 cm). Of the 290 singleton births, 22 (7.6 %) resulted in low birth weight, which compares favorably with that reported by the US National Center for Health Statistics (6.27 %) for the 2013 rate of low birth weight in singleton births [29].

Discussion

Currently, women with MS or CD being treated with natalizumab who are planning to become pregnant or discover they are pregnant after natalizumab exposure are advised to balance the potential benefits and potential risks of exposure when considering treatment options. Although some patients are able to discontinue treatment before or during pregnancy, others with more severe disease may elect to continue treatment. Thus, this Registry was undertaken to prospectively gather important information about pregnancy outcomes in patients exposed to natalizumab. In the Registry, the rate of reported birth defects in the infants of women exposed to natalizumab during pregnancy was higher than the 2.67 % observed in the MACDP. No specific pattern of malformations was seen within the observed birth defects. The rate of spontaneous abortions was consistent with the general population [2628].

Natalizumab prevents leukocyte migration by binding to α4 integrins that are expressed on the surface of leukocytes [6]. However, reproductive and/or fetal development processes may be affected by inhibition of α4 integrins; of particular note are the processes of fertilization, placental development, embryo implantation, hematopoiesis, and cardiac development [3035]. Natalizumab has been categorized as a pregnancy category C medication based on animal studies showing transplacental crossing and potential for offspring effects, such as reduced pup survival in guinea pigs and mild anemia or reduced platelet count in the fetus of monkeys [6, 12, 13]. However, no treatment-related teratogenic effects were observed, including no cardiac abnormalities observed in any natalizumab study, in contrast to the published role of α4 in the formation of the epicardium and consequent cardiac abnormalities in α4 null mice [12, 16, 34].

Animal studies provide valuable information, but human studies are also necessary to understand maternal and neonatal outcomes. Hellwig et al reported no decreased fetal growth or teratogenicity in 35 patients who received natalizumab for ≥8 weeks prior to their last menses and discontinued treatment as soon as they became aware of the pregnancy [17]. In these patients, the rate of spontaneous abortions (14.3 % [5 of 35]) was higher than that observed in the Registry (9.0 %). Of the remaining 30 patients in their study, 1 underwent an elective termination, and 29 women birthed 28 healthy newborns and 1 infant with a hexadactyly defect that was also captured in this Registry. The average birth weight in the natalizumab group (3159 g) was within normal range for full-term infants (i.e., 2500–4000 g [36]), although slightly lower than that in the group of pregnant patients with MS who had not been exposed to disease modifying therapies (3406 g). Additional case reports by Mattioda et al [19], Totaro et al [20], and Hoevenaren et al. [18] did not show any abnormalities in infants at birth and at a 6-week follow-up.

The potential influence of natalizumab exposure at different gestational time points should be considered. Case reports by Mattioda et al [19] and Totaro et al. [20] found that first-trimester exposure to natalizumab resulted in uncomplicated gestation and neonatal outcomes (normal fetal growth and full-term delivery). Houtchens et al reported on 2 patients with natalizumab exposure during the first 6 weeks of pregnancy, resulting in 1 healthy infant and 1 miscarriage [15]. Fagius and Burman reported on a patient with MS who continued natalizumab treatment throughout the pregnancy, resulting in an uncomplicated caesarian delivery at full-term and a normal infant at an 8-month follow-up [37]. Although few third-trimester exposures to natalizumab were reported in the Registry, a recent case series of 13 pregnancies in women with aggressive MS observed hematological abnormalities in 10 of 13 newborns following third-trimester exposure to natalizumab [38].

In the Registry, the majority of patients discontinued treatment prior to or within the first trimester. The pregnancies resulting in live births with defects were last exposed to natalizumab within 3 months prior to conception or within the first trimester, with more than half exposed between 1 and 4 weeks of gestation. Of the 4 patients who continued natalizumab treatment during pregnancy, no congenital anomalies were observed in the resulting 4 live births. Interpretation of the Registry data is limited by the duration of natalizumab exposure during pregnancy.

The Registry found no increased risk of pregnancy loss in pregnancy outcomes among women with natalizumab exposure compared with rates in the general population. The spontaneous abortion rate of patients in the Registry (9.0 %) was lower than that observed in the general population (13.1–15.9 %) [26, 27] and consistent with a longitudinal study of untreated pregnant women with MS (9.8 %) [28]. The background rate for spontaneous abortion is difficult to identify with precision, and spontaneous abortions were not captured prior to Registry enrollment, which may present a bias resulting in the underestimation of the true spontaneous abortion rate. However, this ascertainment bias is common to both drug exposure and general population pregnancy registries insofar as spontaneous abortions are most often reported among recognized pregnancies.

Upon review of Registry pregnancy outcomes, the Advisory Committee determined that 16 infants among the 317 (316 live births plus 1 elective termination) had defects that met criteria for major defects. The Registry birth defect rate of 5.05 %, as determined by the Advisory Committee, was higher than the 2.67 % published in the MACDP [25]. No pattern of defects suggestive of an unusual distribution was observed. Because birth outcome reference information specific to untreated MS or CD patient populations is not available, the MACDP was used as an external reference group. However, use of the MACDP as an external reference group is not without limitations. The MACDP registers birth outcomes of ≥20 weeks’ gestation with birth defects in metropolitan Atlanta; therefore, any birth outcomes of <20 weeks’ gestation are not captured. Additionally, unlike the Registry, the MACDP is not disease specific, comprises both healthy and unhealthy pregnancies, and does not target particular exposures. In contrast, the Registry population was a carefully monitored population of patients with MS or CD, which may have increased potential selection and ascertainment bias.

Registry outcomes can be complicated by potential biases inherent to the study population and design. Such biases may result in an overestimate or an underestimate of the reported risk. For example, the protocol permitted enrollment of pregnant patients in the Registry after a prenatal test, as long as testing did not indicate an abnormality. However, this practice could potentially bias the results by lowering the overall risks of birth defects [39]. Other potential factors that might confound pregnancy outcomes include maternal obstetrical history; comorbid medical conditions and medications [40, 41]; lifestyle factors (e.g., smoking or alcohol intake) [42]; and planned versus unplanned pregnancy [43]. Some caveats to consider when interpreting the Registry outcomes include differences in natalizumab exposure duration, differences in pregnancy outcome detection between the Registry and MACDP, and the absence of a comparison group of pregnant women with MS who were not exposed to natalizumab. As noted by the expert Advisory Committee, there is currently no valid and stable estimate of spontaneous abortions or major birth defects among women with MS not treated with natalizumab. In addition, previous efforts to include a comparator arm within an MS treatment pregnancy study have met with enrollment difficulties [44]. Thus, it is difficult to determine whether the outcomes observed in this Registry reflected the effects of natalizumab, underlying MS disease, or other unmeasured conditions.

Conclusions

The Registry prospectively evaluated pregnancy outcomes in patients treated with natalizumab within 3 months of conception or during pregnancy. The overall rate of major birth defects in the Registry was higher than that reported by the MACDP. No specific pattern of birth defects was observed that would suggest a drug effect. The rate of spontaneous abortions was consistent with the expected background rates observed in the general population [2628]. Although not observed in the Registry, one report has described transient hematological abnormalities in infants exposed to natalizumab during the third trimester [38]. The natalizumab prescribing information indicates that natalizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [6]; although the Registry has noted limitations and more research is needed, the findings from the Registry may be informative to clinicians and patients in weighing potential risks and benefits of natalizumab exposure during pregnancy.

Abbreviations

APGAR: 

Appearance, pulse, grimace, activity, and respiration

CC: 

Coordinating center

CD INFORM: 

Crohn’s disease investigating Natalizumab through Further Observational Research and Monitoring

CD: 

Crohn’s disease

MACDP: 

Metropolitan Atlanta Congenital Defects Program

MS: 

Multiple sclerosis

ROW: 

Rest of world

RRMS: 

Relapsing-remitting multiple sclerosis

TPER: 

Tysbari Pregnancy Exposure Registry

TYGRIS: 

Tysabri Global Observational Program in Safety

Declarations

Acknowledgments

Suzie Webster of ConsignMed, Inc., wrote the first draft of the manuscript based on input from authors, Morgan C. Hill, PhD, of Infusion Communications revised the manuscript based on input from authors, and Joshua Safran of Infusion Communications copyedited and styled the manuscript per journal requirements. The authors would like to thank Frances Lynn for valuable contributions to early drafts of the manuscript and the members of the Advisory Committee (Allen Mitchell [Slone Epidemiology Center, Boston, MA], Angela Scheuerle [Tesserae Genetics, Dallas, TX], and Jeffrey Wright [Glen Meade Center for Women’s Heath, Wrightsville Beach, NC]).

Funding

This study was sponsored by Biogen. Statistical analysis was performed by United BioSource Corporation. Biogen provided funding for writing and editorial support in the development of this manuscript. Biogen reviewed and provided feedback on the manuscript to the authors. The authors had full editorial control of the manuscript and provided their final approval of all content.

Availability of data and material

To submit a scientific or medical research proposal requesting access to participant-level data or clinical study reports from the Tysbari Pregnancy Exposure Registry, please visit the WIRB Copernicus Group Data Request Center (https://drc.irbnet.org/release/index.html).

Authors’ contributions

Drafting/revising the manuscript for content, including medical writing for content: SF, SR, GB, LMC, MW. Study concept or design: SR, GB, LMC. Analysis or interpretation of data: SF, SR, GB. Statistical analysis: MW. Study supervision or coordination: GB, SR, LMC. Approval of final manuscript for submission/publication: SF, SR, GB, LMC, MW.

Competing interests

SF, SR, GB, LMC, and MW are employees of and hold stock and/or stock options in Biogen.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Independent ethics committees (Aspire Institutional Review Board, Santee, CA, USA, and Institutional Review Board Services, Auroria, ON, Canada) reviewed and approved this Registry protocol. All patients provided written informed consent and were free to withdraw participation in the Registry at any time.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Biogen, Innovation House
(2)
Biogen

References

  1. Alcalde-Cabero E, Almazán-Isla J, García-Merino A, de Sá J, de Pedro-Cuesta J. Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring. BMC Neurol. 2013;13:58.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Bennett KA. Pregnancy and multiple sclerosis. Clin Obstet Gynecol. 2005;48:38–47.View ArticlePubMedGoogle Scholar
  3. Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler. 2012;18:45–54.View ArticlePubMedGoogle Scholar
  4. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.View ArticlePubMedGoogle Scholar
  5. Coyle PK, Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;10:582–8.View ArticlePubMedGoogle Scholar
  6. Biogen. Tysabri (natalizumab) injection, for intravenous use US prescribing information. 2015. http://www.tysabri.com/prescribingInfo. Accessed 16 June 2015.
  7. Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70:172–82.View ArticlePubMedGoogle Scholar
  8. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356:63–6.View ArticlePubMedGoogle Scholar
  9. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.View ArticlePubMedGoogle Scholar
  10. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.View ArticlePubMedGoogle Scholar
  11. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23.View ArticleGoogle Scholar
  12. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:117–30.View ArticlePubMedGoogle Scholar
  13. Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009;86:108–16.View ArticlePubMedGoogle Scholar
  14. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:144–56.View ArticlePubMedGoogle Scholar
  15. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202–14.View ArticlePubMedGoogle Scholar
  16. Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009;86:98–107.View ArticlePubMedGoogle Scholar
  17. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17:958–63.View ArticlePubMedGoogle Scholar
  18. Hoevenaren IA, de Vries LC, Rijnders RJ, Lotgering FK. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand. 2011;123:430–3.View ArticlePubMedGoogle Scholar
  19. Mattioda A, Masera S, Romagnolo A, Matta M, Superti G, Caligiana L, et al. Healthy baby delivery after conception during natalizumab exposure: a case report [abstract]. Mult Scler. 2011;17:S455–S6.Google Scholar
  20. Totaro R, Rossi M, Casalena A, Carolei A. Pregnancy, delivery, and birth outcome after natalizumab use for multiple sclerosis: a report of two cases [abstract]. Mult Scler. 2011;17:S227–S8.Google Scholar
  21. Committee for Medicinal Products for Human Use. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. . 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf. Accessed 21 Nov 2014.
  22. US Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. 2002. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133332.pdf. Accessed 7 Nov 2014.
  23. US Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf. Accessed 30 Apr 2015.
  24. Correa-Villaseñor A, Cragan J, Kucik J, O’Leary L, Siffel C, Williams L. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol. 2003;67:617–24.View ArticlePubMedGoogle Scholar
  25. Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al. Reporting birth defects surveillance data 1968-2003 [published correction appears in Birth Defects Res A Clin Mol Teratol 2008;82:41-62]. Birth Defects Res A Clin Mol Teratol. 2007;79:65–186.PubMedGoogle Scholar
  26. Anokute CC. Epidemiology of spontaneous abortions—the effect of previous abortions. J R Soc Health. 1987;107:31–3.View ArticlePubMedGoogle Scholar
  27. Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. Stud Fam Plann. 2007;38:187–97.View ArticlePubMedGoogle Scholar
  28. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15:1037–42.View ArticlePubMedGoogle Scholar
  29. Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ. Births: final data for 2013. Natl Vital Stat Rep. 2015;64:1–65.Google Scholar
  30. Grazioli A, Alves CS, Konstantopoulos K, Yang JT. Defective blood vessel development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse embryos. Dev Biol. 2006;293:165–77.View ArticlePubMedGoogle Scholar
  31. Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, et al. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development. 1995;121:489–503.PubMedGoogle Scholar
  32. Sueoka K, Shiokawa S, Miyazaki T, Kuji N, Tanaka M, Yoshimura Y. Integrins and reproductive physiology: expression and modulation in fertilization, embryogenesis, and implantation. Fertil Steril. 1997;67:799–811.View ArticlePubMedGoogle Scholar
  33. Wagner N, Müller W. Functions of alpha 4- and beta 7-integrins in hematopoiesis, lymphocyte trafficking and organ development. Curr Top Microbiol Immunol. 1998;231:23–32.PubMedGoogle Scholar
  34. Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development. 1995;121:549–60.PubMedGoogle Scholar
  35. Fässler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995;9:1896–908.View ArticlePubMedGoogle Scholar
  36. Centers for Disease Control and Prevention. Pediatric and Pregnancy: Nutrition Surveillance System. 2009. http://www.cdc.gov/pednss/what_is/pednss_health_indicators.htm#birthweight. Accessed 30 Apr 2015.Google Scholar
  37. Fagius J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand. 2014;129:e27–e9.View ArticlePubMedGoogle Scholar
  38. Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891–5.View ArticlePubMedGoogle Scholar
  39. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology. 1999;60:356–64.View ArticlePubMedGoogle Scholar
  40. Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010;17:1215–9.View ArticlePubMedGoogle Scholar
  41. Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, et al. CIHR Team in the Epidemiology and Impact of Comomrbidity on Multiple Sclerosis. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology. 2013;40:85–92.View ArticlePubMedGoogle Scholar
  42. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009;15:105–13.View ArticlePubMedGoogle Scholar
  43. Tsui A, Lee MA. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol. 2011;23:435–9.View ArticlePubMedGoogle Scholar
  44. Coyle PK, Sinclair SM, Scheuerle AE, Thorp Jr JM, Albano JD, Rametta MJ. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4:e004536.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement